-transparent.png){kind=logo}
Flavone acetic acid (FAA, NSC 347512) is known to selectively reduce tumor blood flow. Taking advantage of this pharmacodynamic effect, we have previously shown that FAA in combination with hyperthermia (HT) can produce a marked improvement in antitumor response in mice. In the present study, we investigated whether FAA could increase the cytotoxicity of mitomycin C (MMC), a bioreductive drug with selective cytotoxicity against hypoxic cells, under either normothermic or hyperthermic conditions. In vitro, the cytotoxicity of MMC against B16 melanoma cells was not enhanced with exposure to FAA at concentrations less than 100 microgram/ml, even when combined with HT (43 degrees C, 60 min). The cytotoxicity of MMC (1 microgram/ml) at pH 6.5, however, was enhanced by exposure of cells to hypoxia in combination with HT. In vivo, the tumor growth time, calculated as the time required to double the initial tumor volume, was 5.2, 6.8, 8.5, and 15.0 days with FAA (150 mg/kg) alone, MMC (4 mg/kg) alone, FAA + MMC, or FAA + MMC + HT (43 degrees C, 15 min) treatment groups, respectively. Antitumor response obtained in animals treated with FAA plus MMC with HT was clearly better than that obtained in any of the other groups. Scheduling of FAA, MMC, and HT was found to be important in producing optimal antitumor response. Administration of MMC (4 mg/kg) prior to FAA (150 mg/kg) and subsequent HT treatment was superior to administration of FAA before MMC. In an attempt to explain these findings, the influence of FAA on blood flow in skeletal muscle and in tumor was examined using a laser blood flowmeter. FAA administration to mice produced a 75% reduction in blood flow to the tumor for up to 2 h but had no detectable effect on normal skeletal blood flow. Our current explanation of the increased antitumor response achieved with the combination of MMC, FAA, and HT is as follows. The FAA-mediated decrease in blood flow to the tumor, when combined with HT, may produce sufficiently hypoxic conditions to significantly increase the antitumor efficacy of the bioreductive drug, MMC. We believe that clinical testing of this combined drug treatment with hyperthermia is warranted.
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1993,
Anticancer research,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
June 1992,
Cancer research,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1996,
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1992,
Oncology,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1994,
Anticancer research,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
October 1990,
Cancer research,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
March 1989,
European journal of cancer & clinical oncology,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1985,
Medical oncology and tumor pharmacotherapy,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
January 1989,
Bulletin du cancer,
H Takeuchi, and
H Baba, and
Y Maehara, and
K Sugimachi, and
R A Newman
February 1987,
British journal of cancer,
